

REGISTRATION AND PUBLICATION OF THE MINUTES OF SHAREHOLDERS' MEETING. WITHDRAWAL RIGHT.

Saluggia, Italy – 3 March 2025 – Diasorin S.p.A. (FTSE MIB: DIA) (“**Diasorin**” or the “**Company**”) announces that today the minutes of the extraordinary meeting of shareholders (“**Shareholders’ Meeting**”), which on 28 February 2025 approved the proposal to enhance the increased voting rights mechanism adopted by the Company, were registered with the companies’ register of Vercelli.

The minutes of the Shareholders’ Meeting have also been made available to the public at Diasorin’s registered office, on the authorized storage mechanism (www.emarketstorage.com) and on the Company’s website (<https://int.diasorin.com/it>, Section “Group/Governance/Shareholders’ meeting/2025”) pursuant to applicable law.

Diasorin’s shareholders who are entitled and did not participate in the adoption of the resolution on the enhancement of the increased voting rights mechanism (*i.e.*, those shareholders (i) who did not attend the Shareholders’ Meeting or (ii) who attended the Shareholders’ Meeting but voted against the proposed resolution or (iii) who abstained from voting or (iv) whose shares were registered after the record date, *i.e.* 19 February 2025, but before the start of the Shareholders’ Meeting) have the right to withdraw pursuant to applicable law and to the documentation relating to the resolution proposal to the Shareholders’ Meeting.

Information relating to the withdrawal right is included in the notice available on Diasorin’s website (<https://int.diasorin.com/it>, Section “Investors/Financial corner/Press releases”), which will be published on the daily newspaper “*La Stampa*” pursuant to applicable law.

For further details, please refer to the documentation prepared in relation to the resolution proposal to the Shareholders’ Meeting, which has been made available on the Company’s website (<https://int.diasorin.com/it>, Section “Group/Governance/Shareholders’ meeting/2025”).

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 35 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at www.diasorin.com

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

INVESTOR RELATIONS

Riccardo Fava
Corporate VP Communication, ESG & Investor Relations
riccardo.fava@diasorin.it

Eugenia Ragazzo
Corporate Investor Relations & ESG Analyst
eugenia.ragazzo@diasorin.it